Chimerism analysis is crucial
in engraftment monitoring 

Quantitative chimerism analysis is recognized as a powerful diagnostic tool to monitor engraftment. It is based on the quantification of donor-derived, cell-free DNA (dd-cfDNA) circulating in the blood of the transplant recipient. Levels of dd-cfDNA may vary with different dynamics for each type of organ transplanted, but elevated levels of donor-derived DNA after a certain time period generally indicate graft failure.

 
 
Capture.JPG
 
HLA MARKERS AND NON HLA MARKERS YIELD CONCORDANT RESULTS IN CLASSICAL RELAPSES AND DISCORDANT RESULTS IN HLA LOSS RELAPSES. ADAPTED FROM AHCI  ET AL ., BLOOD, 2017


HLA MARKERS AND NON HLA MARKERS YIELD CONCORDANT RESULTS IN CLASSICAL RELAPSES AND DISCORDANT RESULTS IN HLA LOSS RELAPSES. ADAPTED FROM AHCI ET AL., BLOOD, 2017

 

Monitoring of HLA Loss Events Indicates Relapse Before its Actual Onset

Detecting increased mixed chimerism (gradual increase in the proportion of recipient cells) in patients after haploidentical HSCT
is based on comparative evaluation of the presence of HLA
and non HLA markers in bone marrow DNA samples. Results of these tests can provide guidance for rapid clinical decision-making
and choice of intensive salvage treatment.

 

HLA TRACE Assays Represent a Sensitive Solution for HLA Chimerism Monitoring After HSCT

Filling a gap in the scientific and diagnostic follow-up of allogeneic HSCT, the HLA TRACE Assays allow to indicate rapidly imminent post-HSCT HLA loss events before the onset of a relapse via quantitative polymerase chain reaction (qPCR). Alternatively, in combination with the more sensitive digital droplet PCR (ddPCR) methodology, the HLA TRACE Assays enable for a highly accurate and precise chimerism quantification that may form the basis for optimising patient-tailored therapy.

 
image_chromosome_locus4.png